BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luu Y, Bush J, Cheung KJ, Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res. 2002;276:214-222. [PMID: 12027451 DOI: 10.1006/excr.2002.5526] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhong B, Shingyoji M, Hanazono M, Nguyễn TT, Morinaga T, Tada Y, Shimada H, Hiroshima K, Tagawa M. Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype. Apoptosis 2020;25:535-47. [PMID: 32468177 DOI: 10.1007/s10495-020-01612-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang G, Ma N, He F, Kawanishi S, Kobayashi H, Oikawa S, Murata M. Taurine Attenuates Carcinogenicity in Ulcerative Colitis-Colorectal Cancer Mouse Model. Oxid Med Cell Longev 2020;2020:7935917. [PMID: 32566100 DOI: 10.1155/2020/7935917] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lopes EA, Gomes S, Saraiva L, Santos MM. Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. CMC 2020;26:7323-36. [DOI: 10.2174/0929867325666181116124308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Mrozek-wilczkiewicz A, Kuczak M, Malarz K, Cieślik W, Spaczyńska E, Musiol R. The synthesis and anticancer activity of 2-styrylquinoline derivatives. A p53 independent mechanism of action. European Journal of Medicinal Chemistry 2019;177:338-49. [DOI: 10.1016/j.ejmech.2019.05.061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
5 Sundar D, Yu Y, Katiyar SP, Putri JF, Dhanjal JK, Wang J, Sari AN, Kolettas E, Kaul SC, Wadhwa R. Wild type p53 function in p53Y220C mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence. J Exp Clin Cancer Res 2019;38:103. [PMID: 30808373 DOI: 10.1186/s13046-019-1099-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
6 Liu B, Lei M, Hu T, Yu F, Xiao DM, Kang H. Inhibitory effects of SRT1720 on the apoptosis of rabbit chondrocytes by activating SIRT1 via p53/bax and NF-κB/PGC-1α pathways. J Huazhong Univ Sci Technolog Med Sci 2016;36:350-5. [PMID: 27376802 DOI: 10.1007/s11596-016-1590-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
7 Kotipatruni RP, Ren X, Thotala D, Jaboin JJ. NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells. Oncotarget 2015;6:17594-604. [PMID: 26053091 DOI: 10.18632/oncotarget.4009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
8 Harvey TW, Engel JE, Chade AR. Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism. Am J Nephrol 2016;43:74-84. [PMID: 26930122 DOI: 10.1159/000444719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Xu H, Shen F, Lv Q. Celecoxib enhanced the cytotoxic effect of cisplatin in drug-resistant human gastric cancer cells by inhibition of cyclooxygenase-2. European Journal of Pharmacology 2015;769:1-7. [DOI: 10.1016/j.ejphar.2015.09.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
10 Mrozek-Wilczkiewicz A, Spaczynska E, Malarz K, Cieslik W, Rams-Baron M, Kryštof V, Musiol R. Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action. PLoS One 2015;10:e0142678. [PMID: 26599982 DOI: 10.1371/journal.pone.0142678] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
11 Jain A, Bundela S, Tiwari RP, Bisen PS. Oncoapoptotic Markers in Oral Cancer: Prognostics and Therapeutic Perspective. Mol Diagn Ther 2014;18:483-94. [DOI: 10.1007/s40291-014-0104-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
12 Fujiwara T, Morimoto K. A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration. Biochem Biophys Res Commun 2013;440:359-63. [PMID: 23988450 DOI: 10.1016/j.bbrc.2013.08.052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res 2012;746:78-88. [PMID: 22498038 DOI: 10.1016/j.mrgentox.2012.03.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
14 Moushumi Priya A, Jayachandran S. Induction of apoptosis and cell cycle arrest by Bis (2-ethylhexyl) phthalate produced by marine Bacillus pumilus MB 40. Chemico-Biological Interactions 2012;195:133-43. [DOI: 10.1016/j.cbi.2011.11.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
15 Johnson WD, Muzzio M, Detrisac CJ, Kapetanovic IM, Kopelovich L, McCormick DL. Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs. Toxicology 2011;289:141-50. [PMID: 21864638 DOI: 10.1016/j.tox.2011.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang W, Hu Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy: p53-MDM2 PATHWAY FOR CANCER THERAPY. Med Res Rev 2012;32:1159-96. [DOI: 10.1002/med.20236] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
17 Ghosh J, Das J, Manna P, Sil PC. Hepatotoxicity of di-(2-ethylhexyl)phthalate is attributed to calcium aggravation, ROS-mediated mitochondrial depolarization, and ERK/NF-κB pathway activation. Free Radical Biology and Medicine 2010;49:1779-91. [DOI: 10.1016/j.freeradbiomed.2010.09.011] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
18 Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L, Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 2010;70:6566-76. [PMID: 20682800 DOI: 10.1158/0008-5472.CAN-10-0942] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
19 Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010;2:a001222. [PMID: 20463003 DOI: 10.1101/cshperspect.a001222] [Cited by in Crossref: 105] [Cited by in F6Publishing: 139] [Article Influence: 8.8] [Reference Citation Analysis]
20 Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol 2010;220:509-20. [PMID: 20087881 DOI: 10.1002/path.2670] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
21 Selivanova G. Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 2010;20:46-56. [PMID: 20206268 DOI: 10.1016/j.semcancer.2010.02.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 4.9] [Reference Citation Analysis]
22 Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, Rossman R, Mallams A, Doll R, Liu M, Seidel-Dugan C, Bishop WR, Dasmahapatra B. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 2010;285:10198-212. [PMID: 20124408 DOI: 10.1074/jbc.M109.083469] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
23 Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 2009;69:8175-82. [PMID: 19826045 DOI: 10.1158/0008-5472.CAN-09-1377] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
24 Gamlen T, Richards KH, Mankouri J, Hudson L, McCauley J, Harris M, Macdonald A. Expression of the NS3 protease of cytopathogenic bovine viral diarrhea virus results in the induction of apoptosis but does not block activation of the beta interferon promoter. J Gen Virol 2010;91:133-44. [PMID: 19793904 DOI: 10.1099/vir.0.016170-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
25 Buganim Y, Rotter V. p53: Balancing tumour suppression and implications for the clinic. European Journal of Cancer 2009;45:217-34. [DOI: 10.1016/s0959-8049(09)70037-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Lu C, El-deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009;14:597-606. [DOI: 10.1007/s10495-009-0330-1] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
27 Zhao M, Zhang Y, Wang C, Fu Z, Liu W, Gan J. Induction of Macrophage Apoptosis by an Organochlorine Insecticide Acetofenate. Chem Res Toxicol 2009;22:504-10. [DOI: 10.1021/tx800358b] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
28 Patel S, Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs. 2008;17:1865-1882. [PMID: 19012502 DOI: 10.1517/13543780802493366] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 5.5] [Reference Citation Analysis]
29 Sirintrapun SJ, Parwani AV. Molecular Pathology of the Genitourinary Tract: Prostate and Bladder. Surg Pathol Clin 2008;1:211-36. [PMID: 26837907 DOI: 10.1016/j.path.2008.08.002] [Reference Citation Analysis]
30 Rao CV, Swamy MV, Patlolla JM, Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res 2008;68:7670-5. [PMID: 18794156 DOI: 10.1158/0008-5472.CAN-08-1610] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
31 Zache N, Lambert JM, Rökaeus N, Shen J, Hainaut P, Bergman J, Wiman KG, Bykov VJ. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008;2:70-80. [PMID: 19383329 DOI: 10.1016/j.molonc.2008.02.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
32 Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008;20:90-6. [PMID: 18043262 DOI: 10.1097/CCO.0b013e3282f31d6f] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
33 Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 2007;117:3753-64. [PMID: 18060030 DOI: 10.1172/JCI32481] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 6.8] [Reference Citation Analysis]
34 Michod D, Widmann C. DNA-damage sensitizers: Potential new therapeutical tools to improve chemotherapy. Critical Reviews in Oncology/Hematology 2007;63:160-71. [DOI: 10.1016/j.critrevonc.2007.04.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
35 Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007;26:2243-54. [DOI: 10.1038/sj.onc.1210295] [Cited by in Crossref: 128] [Cited by in F6Publishing: 127] [Article Influence: 8.5] [Reference Citation Analysis]
36 Haupt S, Haupt Y. Importance of p53 for cancer onset and therapy. Anticancer Drugs. 2006;17:725-732. [PMID: 16926623 DOI: 10.1097/01.cad.0000217422.52208.fa] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
37 Mitra AP, Datar RH, Cote RJ. Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification. JCO 2006;24:5552-64. [DOI: 10.1200/jco.2006.08.2073] [Cited by in Crossref: 201] [Cited by in F6Publishing: 185] [Article Influence: 12.6] [Reference Citation Analysis]
38 Römer L, Klein C, Dehner A, Kessler H, Buchner J. p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte. Angew Chem 2006;118:6590-611. [DOI: 10.1002/ange.200600611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
39 Römer L, Klein C, Dehner A, Kessler H, Buchner J. p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts. Angew Chem Int Ed 2006;45:6440-60. [DOI: 10.1002/anie.200600611] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
40 Butler JS, Loh SN. Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature. Protein Sci 2006;15:2457-65. [PMID: 17001034 DOI: 10.1110/ps.062324206] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
41 Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006;13:921-6. [DOI: 10.1038/sj.cdd.4401921] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 6.4] [Reference Citation Analysis]
42 Boonmars T, Wu Z, Nagano I, Takahashi Y. What is the role of p53 during the cyst formation of Trichinella spiralis ? A comparable study between knockout mice and wild type mice. Parasitology 2005;131:705-12. [PMID: 16255829 DOI: 10.1017/S0031182005008036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
43 Ho C, Li G. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis. Br J Dermatol 2005;153:900-10. [DOI: 10.1111/j.1365-2133.2005.06810.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
44 Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713-725. [PMID: 16110317 DOI: 10.1038/nrc1697] [Cited by in Crossref: 495] [Cited by in F6Publishing: 454] [Article Influence: 29.1] [Reference Citation Analysis]
45 Nakanishi H, Yasui K, Ikehara Y, Yokoyama H, Munesue S, Kodera Y, Tatematsu M. Establishment and characterization of three novel human gastric cancer cell lines with differentiated intestinal phenotype derived from liver metastasis. Clin Exp Metastasis 2005;22:137-47. [PMID: 16086234 DOI: 10.1007/s10585-005-6526-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
46 Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005;23:4776-4789. [PMID: 16034054 DOI: 10.1200/jco.2005.05.081] [Cited by in Crossref: 371] [Cited by in F6Publishing: 350] [Article Influence: 21.8] [Reference Citation Analysis]
47 Tanner S, Barberis A. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed 2004;3:5. [PMID: 15548325 DOI: 10.1186/1477-5751-3-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
48 Demma MJ, Wong S, Maxwell E, Dasmahapatra B. CP-31398 Restores DNA-binding Activity to Mutant p53 in Vitro but Does Not Affect p53 Homologs p63 and p73. Journal of Biological Chemistry 2004;279:45887-96. [DOI: 10.1074/jbc.m401854200] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
49 Stanhope-baker P, Kessler PM, Li W, Agarwal ML, Williams BR. The Wilms Tumor Suppressor-1 Target Gene Podocalyxin Is Transcriptionally Repressed by p53. Journal of Biological Chemistry 2004;279:33575-85. [DOI: 10.1074/jbc.m404787200] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
50 Wang T, Chen F, Chen Z, Wu YF, Xu XL, Zheng S, Hu X. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 2004; 10(15): 2205-2208 [PMID: 15259066 DOI: 10.3748/wjg.v10.i15.2205] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 76] [Article Influence: 5.2] [Reference Citation Analysis]
51 Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci. 2003;116:4077-4085. [PMID: 12972501 DOI: 10.1242/jcs.00739] [Cited by in Crossref: 746] [Cited by in F6Publishing: 912] [Article Influence: 41.4] [Reference Citation Analysis]
52 Yang Y, Li CC, Weissman AM. Regulating the p53 system through ubiquitination. Oncogene. 2004;23:2096-2106. [PMID: 15021897 DOI: 10.1038/sj.onc.1207411] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 7.3] [Reference Citation Analysis]
53 Perona R, Sánchez-Pérez I. Control of oncogenesis and cancer therapy resistance. Br J Cancer 2004;90:573-7. [PMID: 14760366 DOI: 10.1038/sj.bjc.6601552] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
54 Bykov V, Selivanova G, Wiman K. Small molecules that reactivate mutant p53. European Journal of Cancer 2003;39:1828-34. [DOI: 10.1016/s0959-8049(03)00454-4] [Cited by in Crossref: 91] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
55 Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502-516. [PMID: 12835670 DOI: 10.1038/nrc1123] [Cited by in Crossref: 744] [Cited by in F6Publishing: 740] [Article Influence: 39.2] [Reference Citation Analysis]
56 Wang W, Takimoto R, Rastinejad F, El-Deiry WS. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003;23:2171-81. [PMID: 12612087 DOI: 10.1128/MCB.23.6.2171-2181.2003] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 5.3] [Reference Citation Analysis]
57 Luu Y, Li G. The p53-Stabilizing Compound CP-31398 Enhances Ultraviolet-B-Induced Apoptosis in a Human Melanoma Cell Line MMRU. Journal of Investigative Dermatology 2002;119:1207-9. [DOI: 10.1046/j.1523-1747.2002.19517.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]